Kisqali is a prescription drug used with other medications to treat certain kinds of breast cancer. Kisqali can cause side effects that range from mild to serious, such as fatigue, hair loss, and ...

Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease.

The FDA approved Kisqali for patients with stage 2 or 3 breast cancer and who are at high risk of recurrence. In a phase 3 trial, Kisqali reduced the risk of patients' breast cancer coming back by ...

How Do I Take Kisqali? Kisqali is taken as a tablet that you swallow. You take Kisqali once a day for 21 days in a row, and then have 7 days where you do not take Kisqali. This means that in every ...

This risk is different for everyone, depending on many factors, but should not be underestimated," said Valarie Worthy, co-founder & vice president of community outreach and engagement, Touch, The ...

“We continue to transform cancer care with Kisqali, building on its established profile in the metastatic setting and now helping a wide range of people as they strive to stay cancer-free ...

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment ...

Novartis NVS announced positive data on breast cancer drug Kisqali (ribociclib) from the late-stage study, NATALEE. This late-breaking data from this four-year post-hoc analysis was presented at ...

Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free benefits in a breast cancer subset. For patients with hormone receptor ...

Ribociclib 200mg; with letrozole 2.5mg; tabs. Ribociclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6. These kinases are activated upon binding to D-cyclins and play a crucial role in ...